When enzalutamide-treated breast cancer cells were incubated with CEA-specific CTLs, their sensitivity to CTL-mediated lysis was improved regardless of AR expression, as the sensitivity of AR- MDA MB 231 cells (Figure 3C) was increased to the same extent as AR+ ZR75-1 (Figure 3A) and BT549 cells (Figure 3B). The gene discussed is CEACAM5; the disease is breast cancer.